Beckman Coulter looks to emerging flow cytometry markets with Blue Ocean buy
This article was originally published in Clinica
Executive Summary
In its first acquisition since it was taken over by Danaher last year, Beckman Coulter has acquired Blue Ocean Medical, a developer of "low-complexity" flow cytometry analysers and reagents. The deal would help Beckman increase its share in emerging markets which call for easy-to-use systems that do not require a high level of technical expertise to operate. Financial details of the transaction, carried out via the firm's Beckman Coulter Life Sciences subsidiary, were not disclosed.